Table 3. Base Case Results.

	CLABSI	VAP
Number of cases averted (index ICU stay)	10.81	7.71
Infections averted among attributable deaths	1.73	0.79
Infections averted among discharged alive	9.08	6.91
Health effects (post-discharge from index ICU)
Life expectancy / case
No infection	4.44	4.59
Infection | discharged alive	3.57	3.55
Infection | died
QALY / case
No infection	2.16	2.26
Infection | discharged alive	1.67	1.68
Infection | died
Health benefits from infections averted
LY gained	15.55	10.84
QALY gained	8.12	5.81
Costs
Index ICU savings / case	$16,155.00	$21,163.00
Total index ICU savings	$174,713.09	$163,090.54
Post-discharge from index ICU
No infection / case	$124,737.28	$124,581.68
Infection | survived / case	$108,108.82	$109,670.15
Infection | died / case
Total Cost Savings	($366,901.52)	($201,965.92)
Combining BSI and VAP
Total ICU Gain in LY	26.39
Total ICU Gain in QALY	13.93
Total ICU Inpatient Cost Increase	($337,803.64)
Total ICU downstream Cost Increase	$568,867.44
Intervention Cost / case (CLABSI + VAP)	$7,828.87
Total Intervention Cost / ICU	$145,000.00
Total Cost Increase	$376,063.80
ICER (LE)	$14,250.74
ICER (QALY)	$26,996.33

CLABSI: Central Line-Associated Bloodstream Infection, ICER: Incremental Cost-Effectiveness Ratios, ICU: Intensive Care Unit, LY: Life Years, QALY: Quality-Adjusted Life Years, VAP: Ventilator-Associated Pneumonia